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Abstract
Background: Phenytoin, mainly metabolized by cytochrome P450 enzyme system, has a narrow therapeutic index
and may have adverse effects due to inter-individual variation in the dose requirement and genetic polymorphisms.
This cross-sectional study was done to study the prevalence of cytochrome P450 CYP2C9 polymorphisms in Indian
epileptic children and to see the effect of polymorphisms on serum levels in epileptic children on phenytoin
monotherapy.
Methods: We studied 89 epileptic children of North Indian population, randomly selected, to see the genotypic
and allelic frequency of CYP2C9 and its association with drug levels on phenytoin monotherapy. Analysis was done
using STATA 9 Software. The results were analyzed as prevalence at 95 % C.I. (Confidence Interval). The difference in
mean phenytoin serum levels between wild and mutant alleles was tested using Student`s T test for independent
samples. P value less than 0.05 was considered statistically significant.
Results: CYP2C9*1, *2 & *3 allelic frequencies were 85.4, 4.5 and 10.1 % respectively. CYP2C9*3 allelic group
showed significantly higher serum phenytoin levels compared to the wild variants (P = 0.009). There was no
statistically significant difference in the dose received (P = 0.12) and side effects of CYP2C9*2 and CYP2C9*3
genotypes (P = 0.442 and 0.597 respectively) when compared with wild variant.
Conclusion: CYP2C9*3 is more common than *2 in the present study. All the polymorphisms demonstrated in our
study were heterozygous with no homozygosity. Serum phenytoin levels are higher in polymorphic groups (*3)
which suggest their poor metabolizing nature. Genotyping may help to avoid toxicity and
concentration-dependent adverse effects.
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Background
Epilepsy is a common disorder in pediatric practice, with a
prevalence of 5.59 per 1000 population with no gender or
geographical differences in Indian population [1]. Phenytoin
is one of the commonly prescribed drugs in children for
seizure control. CYP2C9 may be involved in 80–90 % of
metabolism of phenytoin and therefore polymorphisms in
CYP2C9 may result in significant reduction in the metabol-
ism of phenytoin and can enhance clinical toxicity of the
drug [2–4]. CYP2C9 gene is located on the long arm of
chromosome 10 at 10q24, has 10 exons and 1847 bases
coding DNA which codes for 490 amino acid protein.
CYP2C9*2 polymorphism results due to c.430C >T nucleo-
tide change resulting in p.Arg144Cys amino acid change
(rs#1799853) whereas CYP2C9*3 results due to change in
c.1075A >C resulting in p.Ile359leu amino acid change
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(rs#1057910). CYP2C9*1 allelic groups have normal en-
zyme activity whereas the CYP2C9*2 (Cys 144) allelic
groups have reduced enzyme activity, and even lower activ-
ity in CYP2C9*3 (Leu359) variants. In Caucasians, the most
common variant of CYP2C9 is CYP2C9*2 (10–13 % of the
population), whereas the frequency of CYP2C9*3 varies
from 5–9 % [5–7]. In Asians and Africans, these two alleles
appear at lower frequency than seen in the Caucasians [8].
In Chinese and Japanese, the CYP2C9*2 allele has not been
detected [9–11]. Previous genotyping reports in different
ethnic groups in India demonstrate wide differences in the
distribution of the CYP2C9 alleles.
Methods
Baseline characteristics
This is a cross-sectional observational study done be-
tween June 2010 to May 2012, where 89 epileptic chil-
dren (Males:55, Females: 34) of North Indian origin
between age groups 5–12 years with mean age 9.29
(±2.7) years on phenytoin were finally included for ana-
lysis (Fig. 1). Sample size was calculated by anticipating
50 % prevalence of cytochrome P450 CYP2C9 in epi-
lepsy patients to fall within 10 % points of the true pro-
portion with 95 % confidence [12]. Cases were enrolled
from Out-patient department and Neurocysticercosis
Clinic of All India Institute of Medical Sciences. Major-
ity (93.3 %) of cases included were of neurocysticercosis
while rest were having Idiopathic epilepsy (6.7 %). These
patients were on phenytoin monotherapy for at least
1 month or more [Mean duration: 12.7 months, Median
(min, max): 7 (1–78) months] and were on same drug
regimen at the time of drug level measurement. Doses
were adjusted once the phenytoin level was >20 mcg/ml.
None of the children under study had hepatic or renal
dysfunction. Children on polytherapy (more than one
antiepileptic drugs), those with genetic syndromes and
on drugs that interfere with the metabolism of phenytoin
were excluded. Informed written consent was obtained
from parents. The study was approved by the Institute`s
ethics committee (Office of ethics subcommittee, All
India Institute of Medical Sciences, Room no 102, 1st
floor, Old OT block, Ansari Nagar, New Delhi-110029,
Ref No: IESC/T-182/2010).
DNA extraction and genotyping
CYP2C9*2 which codes for amino acid change
Arg144Cys was detected by PCR-RFLP as described [13]
using the following primers; [Forward primer: 5′-cac tgg
ctg aaa gag cta aca gag-3′ (24 bases) and Reverse primer:
5′-gtg ata tgg agt agg gtc acc cac-3′ (24 bases)], to amp-
lify a 375 bp amplicon in a 25 μL PCR mix comprising
2.5 μL 10X buffer, 2.5 μL of 2 mM dNTPs, 1 μL of
10 μM each forward and reverse primers, 0.25 μL Taq
polymerase, 100.5 μL of sterile water and 1 μL of
100 ng/μL genomic DNA. PCR methodology has been
explained in Additional file 1.
Unrestricted PCR products were of 375 bp. After re-
striction digestion, homozygote TT samples at c.430 gave
375 bp only (similar to unrestricted PCR products)
whereas heterozygotes (CT samples) gave 375 bp, 297 bp
and 78 bp products. Homozygote CC samples gave
297 bp and 78 bp products only (Fig. 2).
CYP2C9*3 which is responsible for amino acid change
Ile359Leu was detected by PCR-RFLP assay [13] using
following primers: Forward primer: 5′-agg aag aga ttg
aac gtg tga-3′ (21 bases) and Reverse primer: 5′-ggc agg
Fig. 1 Work plan for the study
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ctg gtg ggg aga agg cca a-3′ (25 bases). PCR conditions
were the same as described (Additional file 1). Unre-
stricted PCR products were of 130 bp. After restriction
digestion, homozygote AA samples at c.1075 gave
130 bp only (similar to unrestricted PCR products)
whereas heterozygotes (AC samples) gave 130 bp,
104 bp and 26 bp products. Homozygote CC samples
gave 104 bp and 26 bp products only (Fig. 3).
Phenytoin estimation
2–3 ml blood sample was collected in plain vial the next
morning after giving the evening dose of phenytoin. The
sample was centrifuged immediately at 10,000 RPM for
10 min. The separated serum was then transferred to
micro-centrifuge tubes and stored at −80 °C till pheny-
toin levels was estimated. Phenytoin level in serum was
estimated by High Performance Liquid Chromatography
(HPLC). Shimadzu (Prominence) HPLC equipment with
Photo Diode Array Detector (PDA) was used at 210 nm.
Agilent Zorbax SB-C18 column was used. Flow rate was
at 1.2 ml/min. The mobile phase consisted of following
ingredients: Potassium dihydrogen orthophosphate buffer
(50 mM): Acetonitrile: Methanol 58:21:21 (v/v/v). The
mobile phase was filtered through 0.22 μm membrane fil-
ter and degassed prior to use. 200 μl of serum was then
vortexed mixed with 20 μl diazepam (3 mg/ml) as internal
standard, then again it was vortexed and mixed with
200 μl acetonitrile (HPLC grade) for 1 min. The mix-
ture was centrifuged at 15000 rpm for 12 min and the
supernatant was separated. 25 μl of the supernatant
was filtered through a 0.4 μM filter and was directly
injected into the HPLC system. Patient samples were
estimated for phenytoin levels by using a standard cali-
bration curve.
Statistical analysis
Genotype frequencies in the study population were
checked for Hardy-Weinberg equilibrium. Analysis was
done using STATA 9 Software. The results were ana-
lyzed as prevalence at 95 % C.I. (confidence Interval).
The difference in mean phenytoin serum levels between
wild and mutant alleles was tested using Student’sT test
for independent samples. P value less than 0.05 was con-
sidered statistically significant.
Fig. 2 Electrophoresis on 2 % agarose gel after digestion with Ava II (Abbreviations: bp-base pairs). Lanes 1–8, 12–18, 20: *1/*2. Lanes 11 and 19:
*1/*2. Lane 9: 100 bp ladder. Lane 10: Unrestricted PCR product
Fig. 3 Electrophoresis on 3 % agarose gel after digestion with Sty I (Abbreviations: bp- base pairs). Lanes 1, 5, 10, 14, 18: *1/*3. Lanes 2–4, 6–9,
11–13, 15–17 and 19: *1/*1. Lane 20: Unrestricted PCR product
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Results
The frequency of CYP2C9*1/*2/*3 alleles were 85.4, 4.5
and 10.1 % respectively. The frequency for *1/*1, *1/*2,
*1/*3 and *2/*3 genotypes was 71.9, 7.9 , 19.1 % and
1.1 % respectively (Table 1). A single individual was het-
erozygous for both *2 and *3 polymorphism. CYP2C9*2
genotyping showed 91 % to be wild (CC) and 9 % were
heterozygous (CT). No homozygous polymorphism was
identified in this study population as expected from the
Hardy Weinberg equilibrium. The frequency of wild al-
leles (C) was 95.5 % and the mutant allele (T) was 4.5 %
(Table 2). Genotyping for CYP2C9*3 showed prevalence
of 79.8 % for the wild (AA) and 20.2 % for the mutant
group (AC). Allele distribution was 89.9 % for the wild
and 10.1 % for the mutant. All of the polymorphisms de-
tected were heterozygous. No homozygosity was identi-
fied (Table 3). The means for phenytoin doses required
in the CC and CT groups did not vary significantly, nei-
ther the difference in phenytoin levels in these two
groups was significant (Table 4). The mean doses (mg/
kg) in AA and AC groups were 5.3 and 4.8 with no sta-
tistically significant results but the median phenytoin
levels compared in both the groups were statistically
significant (P = 0.009) (Table 5). The frequency of side
effects (gum hypertrophy, ataxia, hirsuitism) in both the
polymorphic groups was not statistically significant (P =
0.442 and 0.597 for *2 and *3 genotypes) (Table 6).
Discussion
The frequency of *2 alleles in our study was 0.045 which is
less than the reported in Italian, Greek, Russian, Swedish
and Iranian Population. Frequency of *3 in our study popu-
lation was higher than in Chinese, Japanese, Americans,
Russian, and Swedish (Table 7). CYP2C9*2 genotypes are
negligible or almost absent in the Chinese and Japanese
[8–10] while Caucasians have higher frequencies of *2 as
compared to *3 genotypes [6, 9, 14]. CYP2C9*3 alleles in
the Italian and our population was almost similar. The fre-
quencies of CYP2C9 genotypes are given in Table 5.
The frequencies of CYP2C9*2 in Indian population
have found to be between 3–5 % whereas CYP2C9*3
ranges from 4–8 % [15–17]. The allele frequencies of *2
and *3 in Indian population published till date were
found to be almost similar to the present study. A study
done in North Indian population by Rathore et al. re-
vealed similar *2 allelic frequencies with lower *3 allelic
frequencies (0.10 Vs 0.039). Most of these studies have
been carried out on smaller sample size. Our study also
had a small sample size. Therefore, multi-centric studies
with large sample size should be carried out to solve
these discrepancies of the allelic frequency in different
studies in the same population.
We also studied association of the CYP2C9*2 and *3
polymorphisms with phenytoin levels. The median
phenytoin levels (mcg/ml) in the *2 genotypes, both wild
(CC) and mutant (CT) was 6.8 and 9.5 respectively (not
significant). We generally use phenytoin at the dose of
5–8 mg/kg/day and maintain a drug level between 10–
20 mcg/ml at our center. Statistically significant differ-
ence in the drug levels between the CYP2C9*3 wild and
mutant genotypes (P = 0.009) was observed in our study
suggesting the poor metabolizing nature in polymorphic
groups; although there was no significant toxicity in
those groups.
Recent pharmacogenetic studies have demonstrated
the importance of polymorphism with phenytoin levels
[13, 18–20]. In a recent study by Vander Weide et al.
demonstrated that patients with at least one mutant
CYP2C9 allele required a lower dose of phenytoin to
achieve a therapeutic serum drug concentration than did
the patients with two normal alleles [21]. Lee at al also
demonstrated that CYP2C9*3 variants in Korean
Table 1 CYP2C9 alleles and genotypes
CYP2C9 allele and genotype CYP2C9 allele
frequencies (n = 89)
95 % Confidence
interval (%)
CYP2C9*1 85.4 % 80.21–90.59
CYP2C9*2 4.5 % 1.45–7.55
CYP2C9*3 10.1 % 5.67–14.53
CYP2C9*1/*1 71.9 % 62.56–81.24
CYP2C9*1/*2 7.9 % 2.27–13.45
CYP2C9*1/*3 19.1 % 10.93–27.27
CYP2C9*2/*3 1.1 % 0–3.27
CYP2C9*2/*2 0 % 0
CYP2C9*3/*3 0 % 0
Table 2 Genotypes and alleles of CYP2C9*2 with prevalence
and 95 % CI
CYP2C9*2
genotypes
Number (n = 89) Prevalence (%) 95 % CI
CC 81 91 83–96
CT 8 9 3–16
Alleles No of Alleles Frequency 95 % CI
C 170 95.5 91–98
T 8 4.5 1.9–8
Table 3 Genotypes and alleles of CYP2C9*3 with prevalence
and 95 % CI
CYP2C9*3 genotypes Number (n = 89) Prevalence (%) 95 % CI
AA 71 79.8 69–87
AC 18 20.2 12–30
Alleles No of Alleles Frequency 95 % CI
A 160 89.9 84–94
C 18 10.1 6–15
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patients had higher propensity to develop phenytoin in-
duced cutaneous adverse reactions [22]. Kesavan et al.
also demonstrated a higher phenytoin levels and toxicity
in CYP2C9*2 and CYP2C9*3 allelic variants [23].
Similarly the mean serum concentration of phenytoin
of the polymorphic patients with epilepsy was higher
than that for the wild-type alleles both in the mono-
therapy and polytherapy patients in a study done by
Ozkaynakci A et al. [24].
In a recent study done by Yamamoto Y et al. con-
cluded that genotyping could help in estimating the
optimum target dose of phenytoin and may contribute
to avoid toxicity and concentration-dependent adverse
effects [25]. These results show the importance of the
genetic polymorphism analysis of the main metabolizing
enzyme groups of phenytoin for the dose adjustment.
Conclusions
In summary, both the *2 and *3 allelic variants are
commonly seen in the Indian population with
CYP2C9*3 being more common than *2 in the present
study. All the polymorphisms demonstrated in our
study were heterozygous. No homozygosity was seen
in our study which suggests that the homozygous
polymorphism is rare in this population. The fre-
quency of polymorphism has been found to be differ-
ent in different population in India itself and some
studies in the same population has shown conflicting
results which can be solved by conducting larger
multi-centric studies. Although *3 group had signifi-
cantly higher serum phenytoin level when compared
to *1 group, they did not have significantly higher tox-
icity. As the number of patients with toxicity in our
study was small, no further conclusive recommenda-
tions could be made for clinical implications. Geno-
typing of the CYP2C9 gene in patients on antiepileptic
drugs (eg. Phenytoin) may help to overcome the drug
toxicity, choose the right molecule and guide in thera-
peutic drug monitoring.
Ethics
The study was approved by the Institute’s ethics com-
mittee (Office of ethics subcommittee, All India Institute
of Medical Sciences, Room no 102, 1st floor, Old OT
block, Ansari Nagar, New Delhi-110029, Ref No: IESC/
T-182/2010).
Table 4 Comparing wild and mutant genotypes of CYP2C9*2
for dose (mg/kg) and drug level (mcg/ml)
Variables CC (n = 81) CT (n = 8) P value
Dose (mean ± SD) 5.2 ± 1.15 5.1 ± 0.95 0.89
Phenytoin levela (median) 6.8 9.5 0.74
aNon parametric test applied as variability was high (Wilcoxon rank-sum test)
Table 5 Comparing wild and mutant genotypes of CYP2C9*3
for dose (mg/kg) and drug level (mcg/ml)
Variables AA (n = 71) AC (n = 18) P value
Dose (mean ± SD) 5.3 ± 1.20 4.8 ± 0.69 0.12
Phenytoin levela (Median) 5.9 18.8 0.009
aNon parametric test applied as variability was high (Wilcoxon rank-sum test)
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Table 7 Comparison of CYP2C9 (*1, *2, *3) in different
population in relation to the North Indian population
Ethnicity Number *1 *2 *3
Chinese Han [9] 196 0.974 0 0.026
African American [9] 200 0.985 0.010 0.005
European American [9] 200 0.860 0.080 0.060
Japanese [10] 436 0.979 0 0.021
Sweden [26] 430 0.819 0.107 0.074
Egypt [7] 247 0.817 0.118 0.062
Russian [6] 290 0.827 0.105 0.067
Italian [27] 360 0.777 0.125 0.097
UK [14] 297 0.841 0.106 0.052
Japan [8] 828 0.976 0 0.023
Greek [5] 283 0.79 0.128 0.081
Iran [28] 200 0.873 0.127 0
Italian [29] 150 0.648 0.253 0.098
Chinese Mongolian [11] 560 0.970 0 0.030
Indian Studies
Ethnicity Number *1 *2 *3
Tamilian population [15] 135 0.9 0.03 0.07
South Indian population [16] 346 0.88 0.04 0.08
Northern Indian population [17] 102 0.95 0.049 0.039
Present study in North Indian
population (Delhi)
89 0.85 0.045 0.10
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of PCR products (375 bp) were digested overnight at 37 °C with Ava II
(New England Biolabs) for CYP2C9*2 genotyping. A 130 bp amplicon was
digested by Sty 1 (Eco 1301) (Fermentas International Inc) for CYP2C9*3
genotyping. After the overnight digestion, the digested DNA was run
along with the undigested PCR product on a 2 % agarose gel with
ethidium bromide at 150 V in a horizontal electrophoresis system and
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